• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    556.21 -8.60 (-1.52%)
    Streaming Delayed Price Updated: 1:36 PM EDT, Apr 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 225,433
    Open 566.14
    Bid (Size) 555.59 (40)
    Ask (Size) 556.63 (160)
    Prev. Close 564.81
    Today's Range 555.74 - 567.38
    52wk Range 266.98 - 607.89
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
    Via MarketMinute
    Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗
    Via Chartmill
    Topics Economy

    Performance

    YTD
    +12.0%
    +12.0%
    1 Month
    +16.3%
    +16.3%
    3 Month
    +13.6%
    +13.6%
    6 Month
    +22.7%
    +22.7%
    1 Year
    +90.7%
    +90.7%

    More News

    Read More
    News headline image
    Why United Therapeutics (UTHR) Stock Is Up Today
    Via StockStory
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
    Via Chartmill
    United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
    Via Chartmill
    United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss ↗
    Via Chartmill
    News headline image
    United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
    Via StockStory
    News headline image
    Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid
    Via StockStory
    News headline image
    1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm
    Via StockStory
    Topics Firearms
    News headline image
    This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm
    Via StockStory
    News headline image
    Why United Therapeutics (UTHR) Shares Are Sliding Today
    Via StockStory
    Topics Earnings
    News headline image
    The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
    Via Stocktwits
    News headline image
    United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates
    Via StockStory

    Frequently Asked Questions

    Is United Therapeutics Corporation - Common Stock publicly traded?
    Yes, United Therapeutics Corporation - Common Stock is publicly traded.
    What exchange does United Therapeutics Corporation - Common Stock trade on?
    United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for United Therapeutics Corporation - Common Stock?
    The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
    What is the current price of United Therapeutics Corporation - Common Stock?
    The current price of United Therapeutics Corporation - Common Stock is 556.21
    When was United Therapeutics Corporation - Common Stock last traded?
    The last trade of United Therapeutics Corporation - Common Stock was at 04/06/26 01:36 PM ET
    What is the market capitalization of United Therapeutics Corporation - Common Stock?
    The market capitalization of United Therapeutics Corporation - Common Stock is 24.97B
    How many shares of United Therapeutics Corporation - Common Stock are outstanding?
    United Therapeutics Corporation - Common Stock has 25B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.